Despite the pros and cons presented for extending the FDA’s approval of Avastin®, Medicare announced that it will continue to pay for Avastin as off-label treatment for breast cancer.
Whether or not this influences the private insurance companies to follow a similar path is yet to be seen. In the meantime, for now patients under Medicare can relax a bit knowing that Medicare will not not pull coverage of this treatment. If it were to consider withdrawing support, it would require a lengthy process that would also require input from the public. In other words, we will hear about the proposal well in advance to respond.
5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.